Literature DB >> 28529292

Author`s Reply.

Sinan Altan Kocaman1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28529292      PMCID: PMC5469095     

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We would like to thank the authors for their comments on our article in their letter entitled “Epicardial adipose tissue and atrial fibrillation: the other side of the coin.” published in Anatol J Cardiol 2017; 17: 56-63. (1) epicardial adipose tissue (EAT), a special fat depot that is related to visceral fat rather than total adiposity, shares the same microcirculation with the myocardial tissue and coronary vessels. Recent studies have identified EAT as an active organ, which secretes several mediators, called adipokines, affecting the vascular system. In a prior study, we determined that EAT is associated with diastolic dysfunction and left atrial dilatation because of local or systemic effects in untreated hypertensive patients (2). We also revealed that EAT is an independent factor for adverse changes in the carotid intima-media thickness, flow-mediated dilation, and pulse wave velocity (3). Vascular structure and functions were mainly related to EAT, possibly with perivascular adiposity. In our opinion, EAT has two main causative roles in atrial fibrillation (AF) development. The first role is the direct local interactions, which predispose the myocardial tissue to arrhythmic genesis due to abnormal atrial architecture, adipocyte infiltration, and atrial fibrosis (4). The second role is the indirect effects on left atrium reflecting from vasculature, which is mainly related to increased blood pressure because of increase in the peripheral vascular resistance after structural and functional impairment in the vascular endothelium (3). The latter mechanism is also a possible driver of the diastolic heart failure and diastolic dysfunction (2) as well as AF. Therefore, as a phrase, “peripheral resistive” may be more reason-oriented than “diastolic” in heart failure with preserved ejection fraction. These roles may be important in the prevention/management of cardiovascular diseases.
  4 in total

Review 1.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

2.  The independent relationship of epicardial adipose tissue with carotid intima-media thickness and endothelial functions: the association of pulse wave velocity with the active facilitated arterial conduction concept.

Authors:  Sinan A Kocaman; Murtaza E Durakoğlugil; Mustafa Çetin; Turan Erdoğan; Elif Ergül; Aytun Çanga
Journal:  Blood Press Monit       Date:  2013-04       Impact factor: 1.444

3.  Effect of epicardial adipose tissue on diastolic functions and left atrial dimension in untreated hypertensive patients with normal systolic function.

Authors:  Mustafa Çetin; Sinan Altan Kocaman; Murtaza Emre Durakoğlugil; Turan Erdoğan; Elif Ergül; Sitki Dogan; Aytun Canga
Journal:  J Cardiol       Date:  2013-03-06       Impact factor: 3.159

4.  An increase in epicardial adipose tissue is strongly associated with carotid-intima media thickness and atherosclerotic plaque, but LDL only with the plaque.

Authors:  Sinan Altan Kocaman; Oben Baysan; Mustafa Çetin; Tuğba Kayhan Altuner; Ezgi Polat Ocaklı; Murtaza Emre Durakoğlugil; Turan Erdoğan; Mustafa Remzi Karaoğuz
Journal:  Anatol J Cardiol       Date:  2016-08-23       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.